Bad Blood: Secrets and Lies in a Silicon Valley Startup
ISBN-13:
9780525431992
ISBN-10:
0525431993
Edition:
New
Author:
John Carreyrou
Publication date:
2020
Publisher:
Knopf Doubleday Publishing Group
Format:
Paperback
400 pages
FREE US shipping
on ALL non-marketplace orders
Book details
ISBN-13:
9780525431992
ISBN-10:
0525431993
Edition:
New
Author:
John Carreyrou
Publication date:
2020
Publisher:
Knopf Doubleday Publishing Group
Format:
Paperback
400 pages
Summary
Bad Blood: Secrets and Lies in a Silicon Valley Startup (ISBN-13: 9780525431992 and ISBN-10: 0525431993), written by authors
John Carreyrou, was published by Knopf Doubleday Publishing Group in 2020.
With an overall rating of 3.9 stars, it's a notable title among other
Corporate Finance
(Entrepreneurship, Small Business & Entrepreneurship, Infrastructure, Processes & Infrastructure, Finance) books. You can easily purchase or rent Bad Blood: Secrets and Lies in a Silicon Valley Startup (Paperback, Used) from BooksRun,
along with many other new and used
Corporate Finance
books
and textbooks.
And, if you're looking to sell your copy, our current buyback offer is $0.48.
Description
The Financial Times & McKinsey Business Book of the Year
A New York Times Notable Book
A Washington Post Notable Book
One of the Best Books of the Year: NPR, San Francisco Chronicle, Time, Esquire, Fortune, Marie Claire, GQ, Mental Floss, Science Friday, Bloomberg, Popular Mechanics, BookRiot, The Seattle Times, The Oregonian, Publishers Weekly, Library Journal
In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the next Steve Jobs: a brilliant Stanford dropout whose startup “unicorn” promised to revolutionize the medical industry with its breakthrough device, which performed the whole range of laboratory tests from a single drop of blood. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes’s worth at an estimated $4.5 billion. There was just one problem: The technology didn’t work. Erroneous results put patients in danger, leading to misdiagnoses and unnecessary treatments. All the while, Holmes and her partner, Sunny Balwani, worked to silence anyone who voiced misgivings—from journalists to their own employees.
Rigorously reported and fearlessly written, Bad Blood is a gripping story of the biggest corporate fraud since Enron—a tale of ambition and hubris set amid the bold promises of Silicon Valley.
A New York Times Notable Book
A Washington Post Notable Book
One of the Best Books of the Year: NPR, San Francisco Chronicle, Time, Esquire, Fortune, Marie Claire, GQ, Mental Floss, Science Friday, Bloomberg, Popular Mechanics, BookRiot, The Seattle Times, The Oregonian, Publishers Weekly, Library Journal
In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the next Steve Jobs: a brilliant Stanford dropout whose startup “unicorn” promised to revolutionize the medical industry with its breakthrough device, which performed the whole range of laboratory tests from a single drop of blood. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes’s worth at an estimated $4.5 billion. There was just one problem: The technology didn’t work. Erroneous results put patients in danger, leading to misdiagnoses and unnecessary treatments. All the while, Holmes and her partner, Sunny Balwani, worked to silence anyone who voiced misgivings—from journalists to their own employees.
Rigorously reported and fearlessly written, Bad Blood is a gripping story of the biggest corporate fraud since Enron—a tale of ambition and hubris set amid the bold promises of Silicon Valley.
We would LOVE it if you could help us and other readers by reviewing the book
{user}
{createdAt}
{truncated_title}
{author_block}
by {truncated_author}
